ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1020

Far Infrared Radiation on the Arteriovenous Fistula Induces Changes in VCAM and ICAM in Patients on Hemodialysis

Session Information

Category: Dialysis

  • 703 Dialysis: Vascular Access


  • Lindhard, Kristine, Herlev Hospital, Herlev, Denmark
  • Jensen, Boye, Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Pedersen, Brian Lindegaard, Rigshospitalet, Kobenhavn, Denmark
  • Meyer-Olesen, Christine Louise, Herlev Hospital, Herlev, Denmark
  • Rix, Marianne, Rigshospitalet, Kobenhavn, Denmark
  • Hansen, Henrik Post, Herlev Hospital, Herlev, Denmark
  • Schalkwijk, Casper, Universiteit Maastricht, Maastricht, Limburg, Netherlands
  • van de Waarenburg, Marjo, Universiteit Maastricht, Maastricht, Limburg, Netherlands
  • Heaf, James G., Sjaellands Universitetshospital Roskilde, Roskilde, Sjaelland, Denmark
  • Hansen, Ditte, Herlev Hospital, Herlev, Denmark

The risk of stenosis in the arteriovenous fistula (AVF) in hemodialysis patients is substantial. Development of an AVF stenosis is due to neointimal hyperplasia. Far infrared radiation (FIR) is a non-invasive intervention with a potentially beneficial effect on AVF patency and survival, although the mechanism is not fully understood. The aim of this study was to investigate the effect of a single FIR treatment on inflammatory and vasodilating factors


Forty hemodialysis patients with an AVF from the Faith-in-Fistula-Trial were included in the study. Each patient was randomized to receive either FIR (FIR group) or no FIR (control group). Blood samples were drawn from the AVF arm and the non-AVF arm before (T0) and after (T40) treatment in both groups during a hemodialysis session. The changes (median [interquatile range]) in several inflammatory and vasodilating factors during FIR were explored in both groups.


In the FIR group 19 patients were included, 21 patients in the control group. No differences in baseline characteristics between the groups were seen. After one FIR treatment, both Vascular Cell adhesion molecule (VCAM) and Intercellular adhesion molecule (ICAM) changed, although the change was significantly lower in the AVF arm compared to the control group. VCAM: -31.55 (-54.33;22.1) vs. -89.87 (-121.55;-29.31), p:0.005 and ICAM: -24.19 (-43.53;25.26) vs. -49 (-79.91;-11.58), p:0.02. Other factors, such as interleukines, nitric oxide and tumor-necrosis-factor 1 also declined, but with no significant differences related to FIR


A single FIR treatment attenuated the decrease in VCAM and ICAM in the AVF arm compared to a control group. These findings do not support the hypothesis of FIRs beneficial effects on the endothelium, although the long term effects of FIR on these factors and their beneficial effects are unknown.


  • Private Foundation Support